2631703-41-6

Enpp-1-IN-12 (100 mg/kg; p.o.) inhibits tumor growth in LLC1 syngeneic murine tumor model for lung cancer^[1].
Enpp-1-IN-12 (10 mg/kg; p.o.) exhibits moderate oral bioavailability (F=45.1%), half-life (t_1/2=1.04 h), and C_max (303.10 ng/mL) in healthy female BALB/c mice^[1].
Enpp-1-IN-12 (1 mg/kg; i.v.) exhibits half-life (t_1/2=0.76 h), C_max (308.64 ng/mL), and CL of 73.22 mL/min/kg in healthy female BALB/c mice^[1].